Gail Lewis Phillips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gail Lewis Phillips has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Denkert
Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
44 shared publications - Charles E. Geyer
University of Pittsburgh, Pittsburgh, PA
44 shared publications - Chiara Lambertini
F. Hoffmann-La Roche Ltd, Basel, Switzerland
44 shared publications - Chiun-Sheng Huang
Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan
44 shared publications - Chunyan Song
Genentech Inc, South San Francisco, CA
44 shared publications - Eleftherios P. Mamounas
Orlando Health Cancer Institute, Orlando, FL
44 shared publications
Latest Publications
- 29 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (2) , 251-253
Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan
- 29 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (2) , 251-253
Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib and GDC-0077 have increased potency in PIK3CA-mutant cancer cells
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib and GDC-0077 have increased potency in PIK3CA-mutant cancer cells
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Activity of GDC-0077 in combination with Palbociclib and/ or Fulvestrant
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Activity of GDC-0077 in combination with Palbociclib and/ or Fulvestrant
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
RTK activity plays a key role in regulating p110a degradation
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
RTK activity plays a key role in regulating p110a degradation
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib-mediated degradation of mutant p110a occurs preferentially at the plasma membrane.
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib-mediated degradation of mutant p110a occurs preferentially at the plasma membrane.
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib depletes mutant p110a protein through ubiquitin and proteasome mechanism in a dose and time dependent manner
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib depletes mutant p110a protein through ubiquitin and proteasome mechanism in a dose and time dependent manner
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib and GDC-0077 induce mutant p110a and not WT p110a degradation
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Taselisib and GDC-0077 induce mutant p110a and not WT p110a degradation
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Data from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity and a manageable safety profile in patients with PIK3CA-mutant breast cancer. However, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent mutant p110a degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression. This study establishes a new strategy for identifying inhibitors that specifically target mutant tumors by selective degradation of the mutant oncoprotein and provide a strong rationale for pursuing PI3Kα degraders in patients with HER2-positive breast cancer.Significance:The PI3K inhibitors GDC-0077 and taselisib have a unique mechanism of action; both inhibitors lead to degradation of mutant p110a protein. The inhibitors that have the ability to trigger specific degradation of mutant p110a without significant change in wild-type p110a protein may result in improved therapeutic index in PIK3CA-mutant tumors.See related commentary by Vanhaesebroeck et al., p. 20.This article is highlighted in the In This Issue feature, p. 1
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity and a manageable safety profile in patients with PIK3CA-mutant breast cancer. However, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent mutant p110a degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression. This study establishes a new strategy for identifying inhibitors that specifically target mutant tumors by selective degradation of the mutant oncoprotein and provide a strong rationale for pursuing PI3Kα degraders in patients with HER2-positive breast cancer.Significance:The PI3K inhibitors GDC-0077 and taselisib have a unique mechanism of action; both inhibitors lead to degradation of mutant p110a protein. The inhibitors that have the ability to trigger specific degradation of mutant p110a without significant change in wild-type p110a protein may result in improved therapeutic index in PIK3CA-mutant tumors.See related commentary by Vanhaesebroeck et al., p. 20.This article is highlighted in the In This Issue feature, p. 1
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Comparison of HER2 expression heterogeneity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. Patients were categorized according to whether HER2 staining was focal (<30%), heterogeneous (30–79%), or homogeneous (≥80%) based on the total percentage of cells stained with 2+ and 3+ intensity. IHC, immunohistochemistry; NAT, neoadjuvant therapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Comparison of HER2 expression heterogeneity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. Patients were categorized according to whether HER2 staining was focal (<30%), heterogeneous (30–79%), or homogeneous (≥80%) based on the total percentage of cells stained with 2+ and 3+ intensity. IHC, immunohistochemistry; NAT, neoadjuvant therapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P < 0.05). (F) Hallmark gene sets enriched for genes downregulated in post-NAT surgical versus pre-NAT samples (adjusted P < 0.05). Differential gene expression and pathway analyses were adjusted for tumor content. (G) Multidimensional scaling plot showing the differences in gene expression profiles between pre-NAT and post-NAT surgical samples. AIMS, Absolute Intrinsic Molecular Subtyping; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IFNγ, interferon gamma; IHC, immunohistochemistry; MDS, multidimensional scaling; Med, median; NAT, neoadjuvant therapy; NEG, negative; NES, normalized enrichment score; PAM50, Prediction Analysis of Microarray 50; POS, positive; PR, progesterone receptor.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P < 0.05). (F) Hallmark gene sets enriched for genes downregulated in post-NAT surgical versus pre-NAT samples (adjusted P < 0.05). Differential gene expression and pathway analyses were adjusted for tumor content. (G) Multidimensional scaling plot showing the differences in gene expression profiles between pre-NAT and post-NAT surgical samples. AIMS, Absolute Intrinsic Molecular Subtyping; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IFNγ, interferon gamma; IHC, immunohistochemistry; MDS, multidimensional scaling; Med, median; NAT, neoadjuvant therapy; NEG, negative; NES, normalized enrichment score; PAM50, Prediction Analysis of Microarray 50; POS, positive; PR, progesterone receptor.